A new review paper was published in Oncotarget's Volume 14 on March 31, 2023, entitled, “Crosstalk between triple negative breast cancer and microenvironment.”

Although many advances have been made in the treatment of breast cancer, for triple negative breast cancer (TNBC) these therapies have not significantly increased overall survival. Tumor microenvironment (TME) plays an essential role to develop and control TNBC progression. Many preclinical and clinical studies are ongoing to treat patients with TNBC disease, but effective therapies are currently not available. 

In their new review, researchers Karly Smrekar, Artem Belyakov and Kideok Jin from Albany College of Pharmacy and Health Science discuss recent progress in our understanding of TNBC, advancements in defining mechanisms of TNBC therapies and potential therapeutic strategies to overcome TNBC.

“Technological advancements such as genomics and epigenomics have provided us with vast insight about the complexity of breast cancer. However, one thing has remained the same, the need for the evaluation of three markers. These three markers; the expression of estrogen, progesterone, and HER2, are all molecular targets for treatment regimens, and are relied on by clinicians [1]. Chemotherapy is the staple treatment for TNBC patients. However, they lack the expression of three key therapeutic markers. The lack of therapeutic markers leads to poorer outcomes in TNBC.”

DOI: https://doi.org/10.18632/oncotarget.28397 

Correspondence to: Kideok Jin - kideok.jin@acphs.edu 

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28397

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - triple negative breast cancer, tumor microenvironment, current therapy

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Oncotarget

Crosstalk Between Triple Negative Breast Cancer and Microenvironment

i3 Health is pleased to be hosting Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, a live webinar, on July 12, 2023 at 1:00 pm EST, chaired by Dr. Sara Tolaney and Dr. Ira Bleiweiss. In this video interview, Dr. Tolaney shares a preview of the important topics she will be discussing in the webinar, including approaches to treatment selection, the emerging role of novel therapies, timely management of adverse events, and much more. Watch the video to gain insight into the factors Dr. Tolaney takes into account in the management of TNBC, and register for the webinar on July 12 to hear the complete discussion!

Expert Perspectives in the Management of Triple-Negative Breast Cancer:Webinar Preview, Sara Tolaney

Breast cancer (BC) is one of the most common and deadly cancers worldwide, affecting millions of women every year. However, not all women share the same risk of developing breast cancer. There are many factors that influence this disease, including age, lifestyle, family history, and genetic makeup.

One of the most important aspects of breast cancer research is to identify the genetic factors that predispose some women to develop breast cancer at an early age, especially in different ethnic groups that may have unique genetic variants. This can help to improve the prevention, diagnosis and treatment of breast cancer, as well as to reduce the health disparities among different populations.

In a new study, researchers Gulnur Zhunussova, Nazgul Omarbayeva, Dilyara Kaidarova, Saltanat Abdikerim, Natalya Mit, Ilya Kisselev, Kanagat Yergali, Aigul Zhunussova, Tatyana Goncharova, Aliya Abdrakhmanova, and Leyla Djansugurova from the Institute of Genetics and Physiology, Kazakh Institute of Oncology and Radiology, Al-Farabi Kazakh National University, and Asfendiyarov Kazakh National Medical University aimed to determine the genetic predisposition to early breast cancer in women from Kazakhstan — a population that has not been well studied before. On October 4, 2023, their research paper was published in Oncotarget, entitled, “Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity.”

“Our study may reveal previously uncharacterized population-specific variants that may increase the risk of BC in the Kazakh population.”

Full blog - https://www.oncotarget.org/2023/10/05/genetic-insights-into-early-breast-cancer-in-kazakhstan/

Paper DOI - https://doi.org/10.18632/oncotarget.28518

Correspondence to - Gulnur Zhunussova - gulnur_j@outlook.com, and Nazgul Omarbayeva - nomarbayeva1@gmail.com

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28518

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, breast cancer, early-onset breast cancer, triple negative breast cancer, next-generation sequencing, pathogenic variant, Kazakh population

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Blog: Genetic Insights into Early Breast Cancer in Kazakhstan

At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metastatic triple-negative breast cancer (TNBC). In this interview, he gives us further insight to the results he shared and what these results could mean for the future of the TNBC treatment landscape.

Real-World Use Patterns, Effectiveness, & Tolerability of Sacituzumab Govitecan for TNBC

BUFFALO, NY- November 22, 2023 – A new #research paper was #published in Oncotarget's Volume 14 on October 4, 2023, entitled, “Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity.”

Breast cancer (BC) is the most common type of cancer among women in Kazakhstan. To date, little data are available on the spectrum of genetic variation in Kazakh women with BC.

In this new study, researchers Gulnur Zhunussova, Nazgul Omarbayeva, Dilyara Kaidarova, Saltanat Abdikerim, Natalya Mit, Ilya Kisselev, Kanagat Yergali, Aigul Zhunussova, Tatyana Goncharova, Aliya Abdrakhmanova, and Leyla Djansugurova from the Institute of Genetics and Physiology, Kazakh Institute of Oncology and Radiology, Al-Farabi Kazakh National University, and Asfendiyarov Kazakh National Medical University aimed to identify population-specific genetic markers associated with the risk of developing early-onset BC and test their association with clinical and prognostic factors. 

“To our knowledge, this is the first study using NGS [next-generation sequencing] technology to study the genetic predisposition to early-onset BC women from Kazakhstan and assess their impact on the patients’ clinical outcomes.”

The study included 224 Kazakh women diagnosed with BC (≤40 age). Entire coding regions (>1700 exons) and the flanking noncoding regions of 94 cancer-associated genes were sequenced from blood DNA using MiSeq platform. The researchers identified 38 unique pathogenic variants (PVs) in 13 different cancer-predisposing genes among 57 patients (25.4%), of which 6 variants were novel. In total, 12 of the 38 distinct PVs were detected recurrently, including BRCA1 c.5266dup, c.5278-2del, and c.2T>C, and BRCA2 c.9409dup and c.9253del that may be founder in this population. BRCA1 carriers were significantly more likely to develop triple-negative BC (OR = 6.61, 95% CI 2.44–17.91, p = 0.0002) and have family history of BC (OR = 3.17, 95% CI 1.14–8.76, p = 0.03) compared to non-carriers. 

“This study allowed the identification of PVs specific to early-onset BC, which may be used as a foundation to develop regional expertise and diagnostic tools for early detection of BC in young Kazakh women.”

DOI - https://doi.org/10.18632/oncotarget.28518

Correspondence to - Gulnur Zhunussova - gulnur_j@outlook.com, and Nazgul Omarbayeva - nomarbayeva1@gmail.com

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28518

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, breast cancer, early-onset breast cancer, triple negative breast cancer, next-generation sequencing, pathogenic variant, Kazakh population

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Genetic Predisposition to Early Breast Cancer in Kazakh Women

Triple negative breast cancer is an aggressive form of breast cancer accounting for 10-20% of breast cancers. Triple-negative breast cancers tend to grow and spread more quickly than other types of breast cancer and can return after treatment. Because of this, this type of breast cancer is considered to be more aggressive than other forms of breast cancer. Research shows that some people have a greater chance of developing triple negative breast cancer if they are subject to certain risk factors. And like other types of breast cancer, catching triple negative breast cancer early through routine cancer screening can help improve prognosis.

Equal Hope hosts, Equal Health. Tune in to hear how health experts and Equal Hope clients are working to address and eliminate health disparities in Chicago.

Equal Hope can help you obtain free mammograms, cervical screens, and a medical home, as well as COVID testing and vaccination. Equal Hope can also help you get a referral for emergency services (like food assistance, help with your utilities or your rent). 

Sign up at EqualHope.org or call Equal Hope at 312-942-3368.

Triple Negative Breast Cancer 3-9-24

Data on outcomes in patients with rapidly relapsing TNBC are scarce.  In this podcast Annals of Oncology Editor-in-Chief discusses the IMpassion132 trial with author Prof. Rebecca Dent, of the Division of Medical Oncology, National Cancer Center, Singapore.   IMpassion132 trial was designed to evaluate the anti-PD-L1 agent atezolizumab combined with chemotherapy specifically in patients with TNBC relapsing within 12 months of standard-of-care chemotherapy or surgery for eTNBC.  For the full report on IMpassion132 see https://doi.org/10.1016/j.annonc.2024.04.001

IMpassion132 trial of chemo +/- atezolizumab for early relapsing unresectable LA/metastatic TNBC

Grinch vs Jack Skellington

Did you know not all breast cancers can be treated the same way? In this episode of the HR on the Offensive podcast host Chris Howard, a member from our CSR team Natalie Berkoff, and guest Robin Woolcock, chairman of the UK charity for Triple Negative Breast Cancer (TNBC), pulls back the curtain on one of the most aggressive and least understood forms of the disease. 

The UK charity for Triple Negative Breast Cancer is one of LACE Partners’ chosen charities that we choose to support and to us, support is more than charitable donations, but it is also about raising awareness. That is what we hope to do with today’s podcast. ` 

How HR can better support employees facing Triple Negative Breast Cancer?

Saving women’s lives by eliminating health disparities in IL.

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Are you an HR leader grappling with the complexities of HR tech, transformation, or change management? Then, listen to the HR on the offensive podcast for cutting-edge insights, actionable strategies, and real-world success stories to tackle your biggest HR challenges.

At LACE Partners, we pride ourselves on being a fundamentally different HR consultancy—innovative, and laser-focused on delivering impact. In each episode, we dive into the latest trends, expert advice, and practical solutions to help you stay ahead in a rapidly evolving workplace.

Whether you're looking to drive adoption of new technology, lead organisational change, or simply optimise your HR strategy, you'll leave every episode with fresh perspectives and tools to take your initiatives to the next level.

Subscribe now and join us on the journey to reshape the future of HR

ESMO podcasts offer educational and scientific insights for oncology professionals, covering the latest research, clinical trials, and discussions in cancer care. Topics include highlights from Annals of Oncology and ESMO Open, case-based discussions, expert debates, and content by and for Young Oncologists. Available on Spotify and SoundCloud, these podcasts support continuous learning and multi-professional collaboration in oncology.

New tracks tagged #tnbc